{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T09:18:05Z","timestamp":1773220685939,"version":"3.50.1"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Dianne and Irving Kipnes Foundation"},{"name":"University Hospital Foundation for Medical Research"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","nucmedbio.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.nucmedbio.2017.12.005","type":"journal-article","created":{"date-parts":[[2017,12,27]],"date-time":"2017-12-27T13:19:22Z","timestamp":1514380762000},"page":"51-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Molecular imaging of platelet-derived growth factor receptor-alpha (PDGFR\u03b1) in papillary thyroid cancer using immuno-PET"],"prefix":"10.1016","volume":"58","author":[{"given":"Michael","family":"Wagner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melinda","family":"Wuest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrit","family":"Hamann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Lopez-Campistrous","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd P.W.","family":"McMullen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Wuest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2017.12.005_bb0005","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.nucmedbio.2017.12.005_bb0010","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1016\/j.suronc.2009.04.002","article-title":"Cervical lymph node dissection in papillary thyroid cancer: current trends, persisting controversies, and unclarified uncertainties","volume":"19","author":"Sakorafas","year":"2010","journal-title":"Surg Oncol"},{"key":"10.1016\/j.nucmedbio.2017.12.005_bb0015","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/jso.21234","article-title":"The role of lymphadenectomy in the management of papillary carcinoma of the thyroid","volume":"99","author":"Rotstein","year":"2009","journal-title":"J Surg Oncol"},{"issue":"1","key":"10.1016\/j.nucmedbio.2017.12.005_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"10.1016\/j.nucmedbio.2017.12.005_bb0025","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1530\/EJE-14-0788","article-title":"Therapy of endocrine disease: response and toxicity of small-molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: a systematic review and meta-analysis","volume":"172","author":"Klein Hesselink","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.nucmedbio.2017.12.005_bb0030","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/nrendo.2011.141","article-title":"Multikinase inhibitors: a new option for the treatment of thyroid cancer","volume":"7","author":"Gild","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.nucmedbio.2017.12.005_bb0035","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ctrv.2015.11.003","article-title":"Lenvatinib: role in thyroid cancer and other solid tumors","volume":"42","author":"Cabanillas","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.nucmedbio.2017.12.005_bb0040","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nucmedbio.2017.12.005_bb0045","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomized, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.nucmedbio.2017.12.005_bb0050","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/path.4069","article-title":"Platelet-derived growth factor receptor-\u03b1 promotes lymphatic metastases in papillary thyroid cancer","volume":"228","author":"Zhang","year":"2012","journal-title":"J Pathol"},{"issue":"S1","key":"10.1016\/j.nucmedbio.2017.12.005_bb0055","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4274\/2017.26.suppl.09","article-title":"Redifferentiating thyroid cancer: Selumetinib-enhanced radioiodine uptake in thyroid cancer","volume":"26","author":"Larson","year":"2017","journal-title":"Mol Imaging Radionucl Ther"},{"key":"10.1016\/j.nucmedbio.2017.12.005_bb0060","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1517\/14728222.2011.594044","article-title":"The mTOR protein as a target in thyroid cancer","volume":"15","author":"Souza","year":"2011","journal-title":"Expert Opin Ther Targets"},{"issue":"15suppl","key":"10.1016\/j.nucmedbio.2017.12.005_bb0065","doi-asserted-by":"crossref","first-page":"6091","DOI":"10.1200\/JCO.2016.34.15_suppl.6091","article-title":"Pembrolizumab for advanced papillary or follicular thyroid cancer: preliminary results from the phase 1b KEYNOTE-028 study","volume":"34","author":"Mehnert","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2017.12.005_bb0070","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1172\/JCI89067","article-title":"Sustained ERK inhibition maximizes responses of Braf V600E thyroid cancers to radioiodine","volume":"126","author":"Nagarajah","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nucmedbio.2017.12.005_bb0075","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S1470-2045(16)30166-8","article-title":"Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial","volume":"17","author":"Brose","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.nucmedbio.2017.12.005_bb0080","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1089\/thy.2014.0123","article-title":"BRAF inhibitor Dabrafenib in patients with metastatic BRAF-mutant thyroid cancer","volume":"25","author":"Falchook","year":"2015","journal-title":"Thyroid"},{"key":"10.1016\/j.nucmedbio.2017.12.005_bb0085","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1590\/2359-3997000000245","article-title":"Radioactive iodine-refractory differentiated thyroid cancer: an uncommon but challenging situation","volume":"61","author":"Schmidt","year":"2017","journal-title":"Arch Endocrinol Metab"},{"key":"10.1016\/j.nucmedbio.2017.12.005_bb0090","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3389\/fendo.2015.00176","article-title":"Molecular targeted therapies of aggressive thyroid cancer","volume":"6","author":"Ferrari","year":"2015","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.nucmedbio.2017.12.005_bb0095","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/nrclinonc.2016.19","article-title":"Evolving molecularly targeted therapies for advanced-stage thyroid cancers","volume":"13","author":"Bible","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2017.12.005_bb0100","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00280-015-2832-6","article-title":"A phase I study of MEDI-575, a PDGFR\u03b1 monoclonal antibody, in Japanese patients with advanced solid tumors","volume":"76","author":"Murakami","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.nucmedbio.2017.12.005_bb0105","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s11060-016-2287-6","article-title":"Phase II study of MEDI-575, an anti-platelet-derived growth factor-\u03b1 antibody, in patients with recurrent glioblastoma","volume":"131","author":"Phuphanic","year":"2017","journal-title":"J Neuro-Oncol"},{"key":"10.1016\/j.nucmedbio.2017.12.005_bb0110","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00280-014-2567-9","article-title":"A phase I dose-escalation of MEDI-575, a PDGFR\u03b1 monoclonal antibody, in patients with advanced solid tumors","volume":"74","author":"Becerra","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.nucmedbio.2017.12.005_bb0115","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00280-014-2389-9","article-title":"A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFR\u03b1) monoclonal antibody, in patients with advanced solid tumors","volume":"73","author":"Chiorean","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.nucmedbio.2017.12.005_bb0120","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/cncr.24788","article-title":"Rationale for the development of IMC-3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet-derived growth factor receptor \u03b1","volume":"116","author":"Shah","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.nucmedbio.2017.12.005_bb0125","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s40265-016-0680-2","article-title":"Olaratumab: first global approval","volume":"77","author":"Shirley","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.nucmedbio.2017.12.005_bb0130","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1478-811X-11-97","article-title":"Targeting the PDGF signaling pathway in tumor treatment","volume":"11","author":"Heldin","year":"2013","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.nucmedbio.2017.12.005_bb0135","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.cytogfr.2014.03.003","article-title":"PDGF receptor signaling networks in normal and cancer cells","volume":"25","author":"Demoulin","year":"2014","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.nucmedbio.2017.12.005_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.gene.2017.03.003","article-title":"PDGFs and their receptors","volume":"614","author":"Kazlauskas","year":"2017","journal-title":"Gene"},{"key":"10.1016\/j.nucmedbio.2017.12.005_bb0145","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ebiom.2016.09.007","article-title":"PDGFR\u03b1 regulates follicular cell differentiation driving treatment resistance and disease recurrence in papillary thyroid cancer","volume":"12","author":"Lopez-Campistrous","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.nucmedbio.2017.12.005_bb0150","doi-asserted-by":"crossref","first-page":"83684","DOI":"10.18632\/oncotarget.13299","article-title":"Platelet derived growth factor receptor alpha mediates nodal metastases in papillary thyroid cancer by driving the epithelial-mesenchymal transition","volume":"7","author":"Adewuyi","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.nucmedbio.2017.12.005_bb0155","doi-asserted-by":"crossref","first-page":"9226","DOI":"10.1073\/pnas.97.16.9226","article-title":"Positron emission tomography provides molecular imaging of biological processes","volume":"97","author":"Phelps","year":"2000","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.nucmedbio.2017.12.005_bb0160","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1021\/mp500284t","article-title":"Gallium-68-labeled Affibody molecule for PET imaging of PDGFR\u03b2 expression in vivo","volume":"11","author":"Strand","year":"2014","journal-title":"Mol Pharm"},{"key":"10.1016\/j.nucmedbio.2017.12.005_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2967\/jnumed.113.121814","article-title":"Imaging of platelet-derived growth factor receptor b expression in glioblastoma xenografts using Affibody molecule 111In-DOTA-Z09591","volume":"55","author":"Tolmachev","year":"2014","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2017.12.005_bb0170","doi-asserted-by":"crossref","first-page":"22000","DOI":"10.3390\/molecules201219816","article-title":"Recent advances in the development and application of radiolabeled kinase inhibitors for PET imaging","volume":"20","author":"Bernard-Gauthier","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.nucmedbio.2017.12.005_bb0175","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.nucmedbio.2006.11.004","article-title":"Synthesis and positron emission tomography studies of carbon-11-labeled imatinib (Gleevec)","volume":"34","author":"Kil","year":"2007","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2017.12.005_bb0180","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1021\/bc300037w","article-title":"Comparison of 64Cu-complexing bifunctional chelators for radioimmunoconjugation: labeling efficiency, specific activity and in vitro\/in vivo stability","volume":"23","author":"Cooper","year":"2012","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2017.12.005_bb0185","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1007\/s00259-016-3458-6","article-title":"ImmunoPET to help stratify patients for targeted therapies and to improve drug development","volume":"43","author":"Kraeber-Bodere","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2017.12.005_bb0190","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3390\/ijms18010057","article-title":"Immuno-PET for clinical Theranostic approaches","volume":"18","author":"Bailly","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.nucmedbio.2017.12.005_bb0195","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.2967\/jnumed.111.095596","article-title":"124I-huA33 antibody uptake is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PET","volume":"52","author":"O'Donoghue","year":"2011","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2017.12.005_bb0200","doi-asserted-by":"crossref","first-page":"e0169828","DOI":"10.1371\/journal.pone.0169828","article-title":"Performance of 89Zr-labeled-rituximab-PET as an imaging biomarker to assess CD20 targeting: a pilot study in patients with relapsed\/refractory diffuse large B cell lymphoma","volume":"12","author":"Jauw","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.nucmedbio.2017.12.005_bb0205","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.2967\/jnumed.112.118612","article-title":"64Cu-DOTA-Trastuzumab PET imaging in patients with HER2-positive breast cancer","volume":"54","author":"Tamura","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2017.12.005_bb0210","first-page":"60","article-title":"Immuno-PET of epithelial ovarian cancer: harnessing the potential of CA125 for non-invasive imaging","volume":"4","author":"Sharma","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging Res"},{"key":"10.1016\/j.nucmedbio.2017.12.005_bb0215","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1369\/0022155416673979","article-title":"Variability in platelet-derived growth factor receptor alpha antibody specificity may impact clinical utility of immunohistochemistry assays","volume":"64","author":"Holzer","year":"2016","journal-title":"J Histochem Cytochem"},{"key":"10.1016\/j.nucmedbio.2017.12.005_bb0220","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.nucmedbio.2016.08.011","article-title":"Copper-64 labeled liposomes for imaging bone marrow","volume":"43","author":"Lee","year":"2016","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2017.12.005_bb0225","doi-asserted-by":"crossref","first-page":"779","DOI":"10.2967\/jnumed.111.100073","article-title":"Molecular imaging of very late antigen\u20134 (\u03b14\u03b21 integrin) in the premetastatic niche","volume":"53","author":"Shokeen","year":"2012","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2017.12.005_bb0230","doi-asserted-by":"crossref","first-page":"6609","DOI":"10.1073\/pnas.1016753108","article-title":"PDGFR\u03b1-positive cells in bone marrow are mobilized by high mobility group box 1 (HMGB1) to regenerate injured epithelia","volume":"108","author":"Tamai","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nucmedbio.2017.12.005_bb0235","doi-asserted-by":"crossref","first-page":"e51221","DOI":"10.1371\/journal.pone.0051221","article-title":"Differential expression of surface markers in mouse bone marrow mesenchymal stromal cell subpopulations with distinct lineage commitment","volume":"7","author":"Rostovskaya","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.nucmedbio.2017.12.005_bb0240","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1038\/nprot.2012.125","article-title":"Isolation of mouse mesenchymal stem cells on the basis of expression of Sca-1 and PDGFR-\u03b1","volume":"7","author":"Houlihan","year":"2012","journal-title":"Nat Protoc"},{"key":"10.1016\/j.nucmedbio.2017.12.005_bb0245","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1089\/scd.2007.0024","article-title":"Immune regulation by mesenchymal stem cells derived from adult spleen and thymus","volume":"16","author":"Krampera","year":"2007","journal-title":"Stem Cells Dev"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805117302536?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805117302536?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,24]],"date-time":"2020-10-24T19:36:48Z","timestamp":1603568208000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805117302536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":49,"alternative-id":["S0969805117302536"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2017.12.005","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular imaging of platelet-derived growth factor receptor-alpha (PDGFR\u03b1) in papillary thyroid cancer using immuno-PET","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2017.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}